Condition
T-LGL Leukemia
Total Trials
6
Recruiting
5
Active
5
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Recruiting5
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT02863692Recruiting
Registry of the German CLL Study Group
NCT06716658Phase 2Recruiting
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06530576Phase 2RecruitingPrimary
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
NCT06530550Phase 2Recruiting
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT07019766RecruitingPrimary
National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
NCT04453345Phase 2UnknownPrimary
TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL
Showing all 6 trials